GLPwatch
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.
J Eur Acad Dermatol Venereol · 2025
Last updated 2026-05-28| Journal | J Eur Acad Dermatol Venereol, 2025 |
|---|---|
| Citations | 27 |
| Relative citation ratio | 11.82 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Hair Loss |
Full record and abstract on PubMed 38925559 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.